A new experimental medication that may increase a tumor's sensitivity to the most commonly prescribed ovarian cancer chemotherapy is now being tested at Scottsdale Healthcare.

The drug, known as CBP501, is available to treat 10 women in an ongoing Phase I clinical trial. This is the first time the drug has been tested in humans."This experimental drug not only increases the tumor's sensitivity to the number one treatment for ovarian cancer, it also has few side effects," said Dr. Raoul Tibes, Director of Hemotologic Malignancies and Assistant Investigator at TGen Clinical Research Services at Scottsdale Healthcare.

Read Entire Article